Improving patient outlook in rheumatoid arthritis: Experience with abatacept

Journal of the American Academy of Nurse Practitioners

Volumn 20, Issue 10, 2008, Pages 486-495

  Coughlin, Mary ^a  

^a Clinical Pharmacology Study Group   (United States)

Author keywords

Abatacept; Costimulation modulator; CTLA 4Ig; Health related quality of life; Inadequate response; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ATTITUDE TO HEALTH; DISEASE COURSE; DRUG MONITORING; HEALTH PROMOTION; HOSPITALIZATION; HUMAN; INFORMED CONSENT; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING; NURSING ASSESSMENT; ORGANIZATION AND MANAGEMENT; PATIENT ADVOCACY; PATIENT CARE; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SAFETY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATTITUDE TO HEALTH; DISEASE PROGRESSION; DRUG MONITORING; HEALTH PROMOTION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; INFORMED CONSENT; NURSE PRACTITIONERS; NURSE'S ROLE; NURSING ASSESSMENT; PATIENT ADVOCACY; PATIENT EDUCATION AS TOPIC; PATIENT-CENTERED CARE; QUALITY OF LIFE; SAFETY; SEVERITY OF ILLNESS INDEX;

EID: 54049145062     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2008.00340.x     Document Type: Review

References (46)

1. Abbott 2006). Humira (adalimumab). Prescribing information [Online]. Retrieved April 2, 2007, from http://www.humira.com
2. American College of Rheumatology 2007). Position statement [Online]. Retrieved September 17, 2007, from http://www.rheumatology.org
3. Amgen 2006). Kineret (anakinra). Prescribing information [Online]. Retrieved April 2, 2007, from http://www.kineretrx.com
4. Arthritis Foundation 2006). [Online]. Retrieved June 14, 2007, from http://www.arthritis.org
5. Baecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., et al 2006). Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis and Rheumatism, 54, 692 701.
6. Baert, F., Noman, M., Vermeire, S., Van Assche, G., D'Haens, G., Carbonez, A., et al 2003). Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. New England Journal of Medicine, 348, 601 608.
7. Bartelds, G. M., Wijbrandts, C. A., Nurmohamed, M. T., Stapel, S., Lems, W. F., Aarden, L., et al 2007). Clinical response to adalimumab: The relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the Rheumatic Diseases, March 9; [Epub ahead of print].
8. Bristol-Myers Squibb 2007). ORENCIA (abatacept). Prescribing information [Online]. Retrieved September 17, 2007, from http://www.bms.com
9. Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L. Montori, V 2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Journal of the American Medical Association, 295, 2275 2285.
10. Centrocor 2006). Remicade (infliximab) for IV Injection. Prescribing information [Online]. Retrieved April 2, 2007, from http://www.remicade.com
11. Choy, E. H. Panayi, G. S 2001). Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal Medicine, 344, 907 916.
12. Criscione, L. G. St. Clair, E. W 2002). Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Current Opinion in Rheumatology, 14, 204 211.
13. Emery, P., Kosinski, M., Li, T., Martin, M., Williams, G. R., Becker, J. C., et al 2006). Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. Journal of Rheumatology, 33, 681 689.
14. Erkan, D 2001). Changes in outcomes after 6 months of infliximab in rheumatoid arthritis (RA): A subgroup analysis of methotrexate-receiving and non-receiving patients. Arthritis and Rheumatism, 44, S83.
15. Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B., et al 1993). The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis and Rheumatism, 36, 729 740.
16. Fraenkel, L., Bogardus, S. T., Concato, J., Felson, D. T. Wittink, D. R 2004). Patient preferences for treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases, 63, 1372 1378.
17. Fransen, J., Creemers, M. C. Van Riel, P. L 2004). Remission in rheumatoid arthritis: Agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford, England), 43, 1252 1255.
18. Genentech 2007). RITUXAN (rituximab). Prescribing information [Online]. Retrieved September 17, from 2007, http://www.rituxan.com
19. Genovese, M. C., Becker, J. C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., et al 2005). Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. New England Journal of Medicine, 353, 1114 1123.
20. Haraoui, B 2005). Differentiating the efficacy of tumor necrosis factor inhibitors. Journal of Rheumatology Supplement, 74, 3 7.
21. Kremer, J. M., Dougados, M., Emery, P., Durez, P., Sibilia, J., Shergy, W., et al 2005). Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism, 52, 2263 2271.
22. Kremer, J. M., Genant, H. K., Moreland, L. W., Russell, A. S., Emery, P., Abud-Mendoza, C., et al 2006). Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine, 144, 865 876.
23. Kremer, J. M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., et al 2003). Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. New England Journal of Medicine, 349, 1907 1915.
24. Kvien, T. K 2004). Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics, 22 (2 Suppl 1 12.
25. Lee, D. M. Weinblatt, M. E 2001). Rheumatoid arthritis. Lancet, 358, 903 911.
26. Lipsky, P. E., van der Heijde, D. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., et al 2000). Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. New England Journal of Medicine, 343, 1594 1602.
27. Maini, R., St. Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., et al 1999). Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet, 354, 1932 1939.
28. Mancuso, C. A., Rincon, M., Sayles, W. Paget, S. A 2006). Psychosocial variables and fatigue: a longitudinal study comparing individuals with rheumatoid arthritis and healthy controls. Journal of Rheumatology, 33, 1496 1502.
29. Moldofsky, H 2001). Sleep and pain. Sleep Medicine Reviews, 5, 385 396.
30. National Institute of Arthritis and Musculoskeletal and Skin Diseases 2006). [Online]. Retrieved March 20, 2007, from http://www.niams.nih.gov/hi/ topics/arthritis/rahandout.htm
31. OMERACT 2006). International Consensus Conference on Outcome Measures in Rheumatology [Online]. Retrieved April 2, 2007, from http://www.rheuma21st.com/ archives/report_omeract7_brooks_et_al.html
32. Russell, A. S., Wallenstein, G. V., Li, T., Martin, M. C., Maclean, R., Blaisdell, B., et al 2007). Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Annals of the Rheumatic Diseases, 66, 189 194.
33. Salaffi, F. Stancati, A 2004). [Disability and quality of life of patients with rheumatoid arthritis: assessment and perspectives]. Reumatismo, 56 (Suppl. 1 87 106.
34. Smolen, J. S. Steiner, G 2003). Therapeutic strategies for rheumatoid arthritis. Nature Reviews. Drug Discovery, 2, 473 488.
35. van der Laken, C. J., Voskuyl, A. E., Roos, J. C., Stigter van Walsum, M., de Groot, E. R., Wolbink, G., et al 2007). Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Annals of the Rheumatic Diseases, 66, 253 256.
36. Wasserman, M 2001). Efficacy of infliximab (3 mg/kg) in a population of severe, long-standing RA patients treated in a quaternary care centre. Arthritis and Rheumatism, 44, S82.
37. Weinblatt, M., Combe, B., Covucci, A., Aranda, R., Becker, J. C. Keystone, E 2006). Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis and Rheumatism, 54, 2807 2816.
38. Weinblatt, M., Schiff, M., Goldman, A., Kremer, J., Luggen, M., Li, T., et al 2007). Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial. Annals of the Rheumatic Diseases, 66, 228 234.
39. Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., et al 2003). Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and Rheumatism, 48, 35 45.
40. Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., et al 1999). A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine, 340, 253 259.
41. Weisman, M. H., Durez, P., Hallegua, D., Aranda, R., Becker, J. C., Nuamah, I., et al 2006). Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. Journal of Rheumatology, 33, 2162 2166.
42. Wells, G., Li, T., Maxwell, L., MacLean, R. Tugwell, P 2007). Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. Journal of Rheumatology, 34, 280 289.
43. Westhovens, R., Cole, J. C., Li, T., Martin, M., Maclean, R., Lin, P., et al 2006). Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford, England), 45, 1238 1246.
44. Wolfe, F. Michaud, K 2004). Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: An investigation in 24,831 patients. Journal of Rheumatology, 31, 2115 2120.
45. Wyeth 2006). Enbrel (etanercept) for subcutaneous injection. Prescribing information [Online]. Retrieved April 2, 2007, from http://www.enbrel.com
46. Yamada, A., Salama, A. D. Sayegh, M. H 2002). The role of novel T cell costimulatory pathways in autoimmunity and transplantation. Journal of the American Society of Nephrology, 13, 559 575.